On Air Now

Now Playing

Our Playlist »


Listen Live Now » 95.5 FM Wausau, WI


Current Conditions(Wausau,WI 54403)

More Weather »
65° Feels Like: 65°
Wind: W 6 mph Past 24 hrs - Precip: 0.01”
Current Radar for Zip


Isolated Thunderstorms 79°


Mostly Clear 56°


Scattered Thunderstorms 80°


Breaking News

BREAKING NEWS / URGENT: The State Supreme Court upholds Act 10, Voter ID, and the state's domestic partnership registry

MADISON, Wis (WSAU)  - The Wisconsin State Supreme Court upheld Act 10, the state law that limits the collective bargaining rights of state employees. The law from three years ago sparked protests at the state capital and led to the recall attempt against Governor Scott Walker. The court's ruling in favor of Act 10 was 5-2. Justice Michael Gableman wrote the lead opinion, which was also signed by Justices David Prosser, Pat Roggensack and Annette Ziegler. Justice Patrick Crooks concurre...

Read More »

Pfizer wins EU approval to expand use of Prevenar to children

(Reuters) - Pfizer Inc on Tuesday said the European Commission has approved expanding the use of Prevenar 13, its pneumococcal conjugate vaccine, to older children and adolescents 6 to 17 years old.

The vaccine protects against the potentially fatal effects of pneumococcal disease, a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus.

Children in this age group who have not previously received Prevenar 13 may receive a single dose of the vaccine, Pfizer said.

The European Commission's decision to approve this expanded indication followed submission and review of a Phase 3 trial of Prevenar 13 in 592 healthy children and adolescents, including those with underlying medical conditions such as asthma.

Prevenar 13 was first introduced for use in infants and young children in December 2009 in Europe and is now approved for such use in more than 120 countries.

It is not indicated for the prevention of pneumococcal pneumonia in the pediatric population in the United States.

The vaccine is approved for use in adults 50 years of age and older in more than 80 countries.

(Reporting By Debra Sherman; Editing by Theodore d'Afflisio)